New preclinical work identifies prolyl 3‑hydroxylase 1 (P3H1) as a driver of pancreatic cancer progression and a modulator of the tumor immune microenvironment. Genetic or pharmacologic inhibition of P3H1 reduced tumor growth and altered immune infiltration in models, suggesting the enzyme as a therapeutic vulnerability. The study linked P3H1 activity to extracellular matrix remodeling and immune suppression—mechanisms central to pancreatic ductal adenocarcinoma’s resistance to therapy. Researchers propose that targeting P3H1 could sensitize tumors to immunotherapy or combination regimens. What happened: inhibiting P3H1 slowed pancreatic tumor growth and shifted immune contexture in experimental models. Why it matters: P3H1 represents a novel target in a cancer type with few effective options, opening routes for small‑molecule or biologic programs exploring tumor‑microenvironment modulation.